Skip to main content

Published locations for Asciminib demonstrates superior efficacy than bosutinib in TKI-refractory CML-CP

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Asciminib demonstrates superior efficacy than bosutinib in TKI-refractory CML-CP

User login

  • Reset your password
  • /content/asciminib-demonstrates-superior-efficacy-bosutinib-tki-refractory-cml-cp
  • /hematology-oncology/article/246645/cml/asciminib-demonstrates-superior-efficacy-bosutinib-tki